Reimagine Care

Remi handles first contact with every patient. It texts on a schedule, reads replies written in the patient's own words with large language models, scores symptom severity against oncology protocols, and either resolves the exchange with guidance and education or passes it to a clinician with the conversation attached; the company says Remi closes 54 percent of patient interactions on its own and has handled 431,000 interactions to date. A major Remi update announced in April 2026 uses large language models for more natural conversations that capture symptoms and know when to escalate.

Oncology nurses, APPs and medical assistants in the Virtual Care Center carry the clinical work that follows, alongside home monitoring devices, home treatment logistics and ePRO collection, and Cureety's therapy specific triage logic is being joined to the platform.

A text from Remi is the first contact, and Remi decides whether a clinician is needed. When it escalates, the Virtual Care Center's APPs, nurses and medical assistants, on duty around the clock, receive the full conversation and respond in about nine minutes on average, and during the high risk weeks after CAR T or bispecific infusion patients also get daily video visits. Fewer than 4 percent of encounters reach the referring oncology team, a rate the company reports to partners as a standing measure.

The Remi page says that when a patient needs a human, Remi knows, and the patient page says the approach ensures every patient receives the right care at the right time. Both sentences promise that no patient who needs a clinician is missed, for a system that closes over half its conversations alone; the escalation thresholds behind those protocols are not shown publicly.

Remi runs on large language models the company describes as trained on the symptoms and side effects of cancer care, working over text messages with evidence based protocols for severity and medically reviewed education content. Cureety, which bought the company in September 2026, brings therapy specific monitoring that scores patient reported toxicity on the CTCAE scale, with protocols for antibody drug conjugates, CAR T, bispecifics and oral therapies, and that logic is being joined to Remi.

Home monitoring for advanced therapy patients tracks temperature, heart rate, blood pressure and oxygen saturation with trend based alerts and tight early thresholds. Which models power Remi, which protocols it follows and how changes reach patients are not described.

Large language models power Remi, Cureety's monitoring and triage logic is being joined to the platform after the September 2026 acquisition, and home monitoring devices supply vital signs for advanced therapy patients. Text messaging carries every patient conversation.

None of the model provider, the messaging carrier, the device makers or the hosting provider is named, and no subprocessor list is published.

An actuarial analysis run with Accorded compared 2,344 enrolled patients, each with at least six months in the program, against CMS and MarketScan claims benchmarks. ED visits ran 30 percent lower overall, 41 percent lower among engaged patients and 64 percent lower for patients 65 and older, and the April 2026 report headlines 68.6 percent fewer avoidable ED visits, with its methodology in the downloadable report.

Named programs add their own figures. In Moffitt Cancer Center's initial phase, 97 percent of nearly 7,000 encounters were resolved without reaching Moffitt providers and 2.4 percent ended in an ED referral. At The Center for Cancer and Blood Disorders, 6,100 patients produced 220,000 interactions and avoidable ED visits fell 55 percent in the first six months. A University of Colorado feasibility study looked at home monitoring for CAR T and stem cell transplant patients, and no study of Remi's own triage accuracy is published.

Patient data enters the service through texts to Remi, home monitoring devices and the partner's record, and every interaction is written back into that record. For clinical clients, Reimagine Care handles protected health information as a business associate, using and disclosing it only as the law and each contract allow, according to its website privacy policy of August 24, 2026.

How long Remi's conversations are kept, whether they train the models and whether any are de identified are not described anywhere public.

Reimagine Care works as a business associate of the providers it serves, using and disclosing protected health information only as the law and each contract permit. That commitment appears in a single sentence of the privacy policy for its website, updated August 24, 2026, which otherwise covers site visitors and marketing contacts.

Agreements are signed partner by partner; no business associate agreement or patient facing privacy notice for Remi is posted, and how existing agreements carry over to Cureety is not addressed.

Patient conversations travel by text message, vital signs come from home devices and notes flow into partner records, and no security certification, audit report or trust center covers any of it. The website policy says the company strives to protect personal information and cannot guarantee its security.

The messaging, device and record connections are where patient data moves, and none of them is described in security terms.

Remi decides how serious a patient's symptom is and what happens next. It assesses severity against evidence based protocols, gives self management guidance and medically reviewed education, and closes 54 percent of patient interactions without any person involved, escalating the rest to its clinicians. For CAR T and bispecific patients it adds structured neurological checks and red flag detection.

How this triage relates to FDA rules for clinical decision software is not addressed on the product pages or in the privacy policy.

Remi is run as a human in the loop assistant: its patient education is medically reviewed, its severity checks follow evidence based protocols, and the company employs a director of governance, risk, compliance and digital operations alongside a QA manager. It reports operating measures to partners continuously, from escalation and response times to engagement, which in its Fort Worth program ran from 93 percent in the first month to 65 percent at six months.

How Remi's severity assessments are checked for accuracy, and whether they hold across ages, cancer types, languages or literacy levels, goes unreported. Its users are cancer patients texting about fevers and side effects, often older and sometimes very ill.

Escalated cases arrive at a clinician with Remi's full conversation attached, and every interaction is written into the partner's record, so a disputed exchange can be traced. For value based clients, a portion of Reimagine Care's fees is at risk against the cost savings it promises, and the KPI model it offers before signing defines what will be measured and reviewed jointly.

No accuracy guarantee, remedy for a missed escalation or terms of service are posted.

Documentation flows back into the partner's EMR, and for advanced therapy programs the integration includes standardized order sets, automated program activation, real time dashboards and closed loop notes across clinic, pharmacy and inpatient teams. Every patient interaction is recorded in the partner's existing workflow.

No record system, interface standard or integration partner is named, so the depth of the connection depends on the partner.

Patients reach Remi by plain text message, with no app, portal or password, and advanced therapy patients add connected thermometers, pulse oximeters and blood pressure cuffs. The service is built for patients and partners in the United States.

Where the platform runs, which cloud hosts it, how customers are separated and whether data moves to Cureety's systems after the acquisition are not described.

Each partnership is priced individually, and the company offers to show a prospective partner the KPI model it will report against before any contract: enrollment and engagement, patient and provider experience, the rate of escalation to the provider, avoidable ED use and inbox volume, reviewed jointly on a set cadence. For health plans, ACOs and other risk bearing groups, part of the fee is placed at risk against the cost savings the program promises, and the model fits fee for service contracts as well, producing documentation that supports care management and remote monitoring billing.

No list price, unit of charge or implementation cost is posted.

Cancer patients in active treatment are the population: symptom management for chemotherapy, immunotherapy and oral oncolytic patients, home administration of subcutaneous, intramuscular, intravenous and oral therapies, and an Advanced Therapy Management program for CAR T and bispecific T cell engagers after infusion. Buyers are health systems and cancer centers, community oncology practices, and health plans, ACOs and other risk bearing groups.

Named programs cover part of this. Moffitt Cancer Center expanded its program in May 2026 after an initial phase, and The Center for Cancer and Blood Disorders, a Fort Worth practice treating more than 20,000 patients a year, added CAR T support in June 2026. The service is built for US oncology programs, while its parent Cureety works across five countries.